Floatz logo

65 assets in Childhood Acute Lymphoblastic Leukemia

Therapeutic assets addressing Childhood Acute Lymphoblastic Leukemia, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
cd70-targeting car-t cells
Childhood Acute Lymphoblastic Leukemia
St. Jude Children's Research HospitalP1CC (43)
cd8+ and cd4+ donor memory t-cells-expressing ha1-specific tcr
Childhood Acute Lymphoblastic Leukemia
Fred Hutchinson Cancer CenterP1CC (43)
Dalbavancin
Childhood Acute Lymphoblastic Leukemia
St. Jude Children's Research HospitalP1CC (43)
Kur-502
Childhood Acute Lymphoblastic Leukemia
Athenex, Inc.P1CC (43)
Levofloxacin Iv
Childhood Acute Lymphoblastic Leukemia
St. Jude Children's Research HospitalP1CC (43)
Mesna
Childhood Acute Lymphoblastic Leukemia
St. Jude Children's Research HospitalP1CC (43)
Revumenib
Childhood Acute Lymphoblastic Leukemia
Children's Oncology GroupP1CC (43)
Ruxolitinib
Childhood Acute Lymphoblastic Leukemia
University of ChicagoP1CC (43)
Lacticaseibacillus Paracasei Subsp. Paracasei Cncmi-1518
Childhood Acute Lymphoblastic Leukemia
Comenius UniversityN/AD (30)
Mb-Cart19.1
Childhood Acute Lymphoblastic Leukemia
Miltenyi Biomedicine GmbHN/AD (30)
Mb-Cart20.1
Childhood Acute Lymphoblastic Leukemia
Miltenyi Biomedicine GmbHN/AD (30)
Mb-Cart2019.1
Childhood Acute Lymphoblastic Leukemia
Miltenyi Biomedicine GmbHN/AD (30)
Senl_B19 Autologous Car-T Treatment
Childhood Acute Lymphoblastic Leukemia
Peking University People's HospitalN/AD (30)
Showing 51 to 65 of 65 assets
PreviousPage 2 of 2Next